Second Genome Inc. recently advanced SGM-1019, the company’s primary microbiome drug indicated for inflammatory bowel disease (IBD), to Phase 1 clinical testing to identify an optimal dose. Peter DiLaura, President and the CEO of the company, said ... Read more